Key Insights

Highlights

Success Rate

84% trial completion

Published Results

39 trials with published results (28%)

Research Maturity

74 completed trials (52% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

9.9%

14 terminated out of 141 trials

Success Rate

84.1%

-2.5% vs benchmark

Late-Stage Pipeline

11%

16 trials in Phase 3/4

Results Transparency

53%

39 of 74 completed with results

Key Signals

39 with results84% success14 terminated

Data Visualizations

Phase Distribution

118Total
Not Applicable (16)
Early P 1 (2)
P 1 (37)
P 2 (47)
P 3 (16)

Trial Status

Completed74
Recruiting18
Unknown16
Terminated14
Active Not Recruiting13
Withdrawn3

Trial Success Rate

84.1%

Benchmark: 86.6%

Based on 74 completed trials

Clinical Trials (141)

Showing 20 of 20 trials
NCT07653594Not ApplicableNot Yet Recruiting

TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)

NCT07743164Phase 3Not Yet Recruiting

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

NCT04022213Phase 2Active Not Recruiting

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

NCT05887609Phase 2Recruiting

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

NCT05080946Early Phase 1Recruiting

Using Aspirin to Improve Immunological Features of Ovarian Tumors

NCT05071937Phase 2Recruiting

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

NCT04027868Completed

Genomic BRCA and Extensive ovArian Cancer Testing

NCT05445778Phase 3Active Not Recruiting

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT03430700Phase 2Completed

Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04701645Phase 1Recruiting

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

NCT04295577Completed

Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

NCT04498117Phase 3Active Not Recruiting

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT06290193Phase 2Recruiting

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

NCT02873962Phase 2Active Not RecruitingPrimary

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

NCT06969833Not ApplicableRecruiting

Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma

NCT02758951Phase 2Active Not Recruiting

Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases

NCT06144853CompletedPrimary

The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study.

NCT00515372Phase 1Active Not Recruiting

Depression Treatment and Screening in Ovarian Cancer Patients

NCT06184867Not ApplicableCompleted

Choices About Genetic Testing And Learning Your Risk With Smart Technology

NCT04907643Not ApplicableRecruiting

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Scroll to load more

Research Network

Activity Timeline